Supplementary Appendix:

2	Projecting the impact of SARS-CoV-2 variants on the COVID-19 epidemic and social
3	restoration in the United States: a mathematical modelling study
4	
5	This supplementary document describes in detail the model contruction, calibration, prediction,
6	and estimation of parameters presented in the main text.
7	
8	1. Model contruction
9	
10	1.1 Model structure and formulation
11	We extended a previously published dynamic compartmental model [1] to describe the
12	circulation of two SARS-CoV-2 strains (the wildtype and B.1.1.7 variant) in the US. The
13	population is divided into eighteen compartments (Figure S1), it includes susceptible
14	individuals (S), vaccinated individuals (V), and sixteen compartments in pair infected by wild
15	strains or B.1.1.7 variant. These sixteen compartments are latent infections (E, E_m),
16	asymptomatic infections (A, A_m), undiagnosed infections with mild/moderate (I ₁ , I _{m,1}) and
17	severe/critical symptoms (I2, Im,2), diagnosed infections with mild/moderate (T1, Tm,1) and

severe/critical symptoms (T2, Tm,2), recovered (R, Rm) and deceased (D, Dm) cases,

respectively. The total population size is denoted by N, where $N=S+V+E+A+I_1+I_2+T_1+T_2+R+$ $E_m+A_m+I_{m,1}+I_{m,2}+T_{m,1}+T_{m,2}+R_m$. The model is described by the following system of ordinary differential equations:

$$\begin{split} \frac{dS}{dt} &= -(\lambda_{pub} + \lambda_{n,pub})(S - S_f) - (\lambda_{pu} + \lambda_{m,pub})S_f - wS, \\ \frac{dV}{dt} &= wS - \left[(1 - \varepsilon_r)\lambda_{pub} + (1 - \varepsilon_{n,r})\lambda_{n,pub}\right](V - V_f) - \left[(1 - \varepsilon_r)\lambda_{pu} + (1 - \varepsilon_{n,r})\lambda_{n,pub}\right]V - V_f\right) - \xi N_f, \\ \frac{dN_f}{dt} &= r \left\{ (\lambda_{pub} + \lambda_{m,pub})(S - S_f) + \left[(1 - \varepsilon_r)\lambda_{pub} + (1 - \varepsilon_{n,r})\lambda_{n,pub}\right](V - V_f) \right\} \frac{S_f}{S_f + V_f} - (\lambda_{pu} + \lambda_{n,pub} + \xi)S_f, \\ \frac{dV_f}{dt} &= (r - 1) \left\{ (\lambda_{pub} + \lambda_{m,pub})(S - S_f) + \left[(1 - \varepsilon_r)\lambda_{pub} + (1 - \varepsilon_{n,r})\lambda_{n,pub}\right](V - V_f) \right\} \frac{Y_f}{S_f + V_f} - (\lambda_{pu} + \lambda_{n,pu} + \xi)V_f, \\ \frac{dU_f}{dt} &= (r - 1) \left\{ (\lambda_{pub} + \lambda_{m,pub})(S - S_f) + \left[(1 - \varepsilon_r)\lambda_{pub} + (1 - \varepsilon_{n,r})\lambda_{n,pub}\right](V - V_f) \right\} \frac{Y_f}{S_f + V_f} - (\lambda_{pu}^r + \lambda_{n,pu}^r + \xi)V_f, \\ \frac{dU_f}{dt} &= \lambda_{pub}(S - S_f) + \lambda_{puj}S_f + (1 - \varepsilon_r)\lambda_{pub}(V - V_f) + (1 - \varepsilon_r)\lambda_{pu}V_f - k_fE, \\ \frac{dE_g}{dt} &= \lambda_{n,pub}(S - S_f) + \lambda_{n,pu}S_f + (1 - \varepsilon_{n,r})\lambda_{n,pub}(V - V_f) + (1 - \varepsilon_{n,r})\lambda_{n,pu}V_f - k_fE, \\ \frac{dL_g}{dt} &= \lambda_{pE}(S - S_f) + \lambda_{puj}S_f + (1 - \varepsilon_r)\lambda_{pub}(V - V_f) + (1 - \varepsilon_{n,r})\lambda_{n,pu}V_f - k_fE, \\ \frac{dL_g}{dt} &= \lambda_{pE} - \gamma_0 A, \\ \frac{dA_u}{dt} &= k_i \rho E - \gamma_0 A, \\ \frac{dA_u}{dt} &= k_i \rho E - \gamma_0 A, \\ \frac{dA_u}{dt} &= k_i \rho E_m - \gamma_b A_m, \\ \frac{dI_i}{dt} &= k_i (1 - \rho) E_m - \alpha_i I_{n,i} - k_i I_{n,i} - \gamma_0 I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} - \alpha_i I_{n,i} - k_i I_{n,i} - \gamma_0 I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} - \gamma_i T_{n,i} - k_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} - \gamma_i T_{n,i} - k_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} - \gamma_i I_{n,i} - \gamma_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} - \gamma_i I_{n,i} - \gamma_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} + \gamma_i I_{n,i} - \gamma_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} + \gamma_i I_{n,i} + \gamma_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} + \gamma_i I_{n,i} + \gamma_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} + \gamma_i I_{n,i} + \gamma_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= \alpha_i I_{n,i} + \gamma_i I_{n,i} + \gamma_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= (\mu_i I_{n,i} + \mu_i I_{n,i} + (1 + \mu_{w_i}))\mu_i I_{n,i}, \\ \frac{dI_{n,i}}{dt} &= (\mu_i I_{n,i} + \mu_i I_{n,i} + \gamma_i I_{n,i}, \\ \frac{$$

25 **1.2 The disease progression**

In our model, the number of residents (N) are divided into households members (N_f) and public 26 mebers $(N-N_f)$ to capture varied force of infection in the public settings (e.g. public 27 transportations, supermarkets, offices, etc) and household (home or other private settings). The 28 number of households members (N_f) are dependent on the number of infected individuals and 29 their family member (r), while the rest of residents denote as public mebers $(N-N_f)$. We assumed 30 that the number of the households at risk of infection is the same as the number of individuals 31 infected in public settings because the probability of two or more household members being 32 infected at the same time but at different public venues is very small. The average number of 33 household members (r) in a US family was estimated as 4 [2] and the mean recovery period 34 $(1/\xi)$ of the infected family members was 28 days [3]. The details values of parameters are list 35 in the Table S1. 36

37

A susceptible or vaccinated individual (S,V) may be infected by a SARS-CoV-2 strain (either 38 the wildtype or B.1.1.7) and entered a latent infection stage (E, E_m , *m* denotes variant). Undergo 39 a mean incubation of 5.2 (4.1-7.0) days, a proportion of infected individuals developed 40 symptoms $(I_1, I_{m,1})$ before diagnosis and report $(T_1, T_{m,1})$, while the rest infected individuals 41 (A, A_m) would not show any symptoms and move forward to recovery (R, R_m). Both 42 undiagnosed and diagnosed infected individuals could progress to severe/critical stage (I₂, I_{m.2}, 43 T₂, T_{m,2}) and unalterably occur to death (D, D_m) or recovery, but with varied progress rate on 44 account of medical care. 45

46

47 **1.3 Force of infection**

48 For susceptible individuals (S), the infection rates were denoted by the force of infection 49 $\lambda_{pub}(t), \lambda_{pri}(t), \lambda_{m,pub}(t)$ and $\lambda_{m,pri}(t)$ as shown in eq. (1), which meant the probability of

a susceptible individual infected by wildtype and B.1.1.7 variant in public settings and 50 households. The force of infection was dependent on the number of latent, asymptomatic (E, 51 E_m, A, A_m) and undiagnosed symptomatic infections (I₁, I_{1,m}, I₂, I_{2,m}). Previous studies had 52 reported a 75% lower infectiveness (ε) of latent, asymptomatic individuals (E, A) compared 53 with symptomatic individuals (I1, I2) [4]. For vaccinated individuals (V), the force of infection 54 was supposed to decline that depends on the vaccine's effectiveness for wildtype (ε_V) or B.1.1.7 55 variant $(\varepsilon_{m,V})$ and denoted by $(1 - \varepsilon_V)\lambda_{pub}(t)$, $(1 - \varepsilon_V)\lambda_{pri}(t)$, $(1 - \varepsilon_{m,V})\lambda_{m,pub}(t)$ and 56 $(1 - \varepsilon_{m,V})\lambda_{m,pri}(t).$ 57

$$\begin{aligned} \lambda_{pub}(t) &= \left[(1 - \varepsilon)(E + A) + (I_1 + I_2) \right] \beta_{pub}(t) \frac{1}{N - N_f}, \\ \lambda_{pri}(t) &= \left[(1 - \varepsilon)(E + A) + (I_1 + I_2) \right] \beta_{pri}(t) \frac{1}{N_f}, \\ \lambda_{m, pub}(t) &= \left[(1 - \varepsilon)(E_m + A_m) + (I_{m,1} + I_{m,2}) \right] (1 + \beta_{up}) \beta_{pub}(t) \frac{1}{N - N_f}, \\ \lambda_{m, pri}(t) &= \left[(1 - \varepsilon)(E_m + A_m) + (I_{m,1} + I_{m,2}) \right] (1 + \beta_{up}) \beta_{pri}(t) \frac{1}{N_f}. \end{aligned}$$
(1)

58

$$\lambda_{m,pub}(t) = \left[(1 - \varepsilon)(E_m + A_m) + (I_{m,1} + I_{m,2}) \right] (1 + \beta_{up}) \beta_{pub}(t) \frac{1}{N - N_f},$$

$$\lambda_{m,pri}(t) = \left[(1 - \varepsilon)(E_m + A_m) + (I_{m,1} + I_{m,2}) \right] (1 + \beta_{up}) \beta_{pri}(t) \frac{1}{N_f}.$$

59 Where

60

$$\beta_{pub}(t) = \beta m_{pub}(t)(1 - \theta_1 p_{pub}(t))(1 - \theta_2 q(t)),$$

$$\beta_{pri}(t) = \beta m_{pri}(t)(1 - \theta_2 q(t)),$$
(2)

The force of infection also depends on the effective contacts rate $(\beta_{pub}, \beta_{pri})$ in the population, 61 which are the product of contact number (m_{pub}, m_{pri}) and transmission probability of per-62 contact with wildtype (β) or B.1.1.7 variant (β_m) infections. Previous literature has reported a 63 59% (56-63%) higher transmissibility in B.1.1.7 (β_m) compared with the wildtype (β) [5]. 64

65

To simulate the community strategies for COVID-19 epidemic, we considered three non-66 pharmaceutical interventions (NPIs, i.e., restricting social distancing, insisting mask use, and 67 keeping hand hygiene) to control the force of infection and further reduce infections and deaths. 68

Restricting social distancing in different epidemic stages would reduce the public contact 69 number (m_{pub}) but inversely increase the household contact number (m_{pri}) . Using masks 70 could lower per-contact transmission probability (β, β_m) in public settings that lie with the 71 usage percentage and effectiveness of the masking in preventing infection. Washing hands with 72 soap and water whenever possible are also considered to prevent the spread of COVID-19 73 because it reduces the amount of virus on hands, which means to reduce per-contact 74 transmission probability (β, β_m) in both public settings and household, too. In our model, the 75 effectiveness of masking and handwashing in preventing infection were 85% (95% CI: 66-76 93%) and 42% (50-95%), respectively [6, 7]. Based on the trend of social interventions of 77 public surveys [8, 9], we assumed that the three NPIs as well as the vaccination rate (w) change 78 in different epidemic stages following Logistic function as follow. 79

$$y(t) = y_{ini} + \frac{y_{end} - y_{ini}}{1 + e^{-k(t - t_{mid})}}$$
(3)

Logistic function is a common S-shaped function, the initial stage is roughly exponential growth or reduction; and then it slows down as it starts to saturate; finally, the increase stops when it reaches maturity. Logistic function is dependent on four parameters: (1) the initial value of growth or reduction y_{ini} ; (2) the end value of growth or reduction y_{end} ; (3) the rate of exponential growth or reduction k; (4) the time when apperence of mid value in growth or reduction t_{mid} . The details of Logistic function are list in the **Table S2**.

87

80

88 **2. Model calibration**

89

90 2.1 Data sources

We collected publicly available reportable epidemiological data in the US from Johns Hopkins
University Coronavirus Resource Center [10] and the Centers for Disease Control and

Prevention (CDC) [11, 12]. These websites provided daily confirmed COVID-19 infection cases and death cases from 1st March 2020 to 31st May 2021, the number of COVID-19 vaccination uptakes and variant proportions from 13th December 2020 to 8th May 2021. All four types of data were used to calibrate the model. An additional table file shows this in more detail [see Additional file 1]

98

99 2.2 Model calibration

We calibrated the model by fitting the daily COVID-19 infections, deaths, vaccination, and 100 101 proportion of variants in the US from 1st March 2020 to 31st May 2021, and predicted the daily and cumulative infections and deaths of COVID-19 over the next 12 months (from 1st June 102 2021 to 31st May 2022). We used the nonlinear least-squares method to minimised the Root 103 Mean Squared Error (RMSE) between four types of model-simulated and reported data. Due 104 to the varied orders of magnitude of four data, we standardised these data for the same orders 105 of magnitude by dividing by the max value of the datasets, which could avoid the fitting process 106 automatically skewing larger orders of magnitude data and better match each type of data 107 (Figure 1). We estimated some of the model parameters by data fitting and obtained the other 108 model parameters from the published literatures (Table S1). 109

110

Based on the 'calibrated' scenario, we perturbed model parameters around the 'calibrated' parameter set to generate a band of curves that best describe the data variations and retain a minimal level of RMSE. We randomly generated 200 small 'perturbating factors'. For each of the perturbing factors, we randomly sampled 100 parameter sets based on Latin Hypercube Sampling (LHS) between the parameter range generated by a random walk (adding the perturbing factor in both positive and negative directions). Hence, we obtained 200 groups of various perturbance, and each group has 100 randomised parameter sets. For each of the 200 groups, we calculated the number of data points covered by the band of curves simulated by the 100 parameter sets and their RMSE. We hence selected the one with the minimal RMSE across 200 bands as the set of simulations that best explained the observed data. The 100 curves in the selected band were used to calculate the 95% CI of the model outcomes. The vaccine effectiveness against B.1.1.7 was estimated spontaneously during model calibration. We validated that the estimated effectiveness of 88.5% produced the lowest RMSE in Figure S2.

124

125 2.3 Model validation for estimated vaccines effectiveness on B.1.1.7 variant

To estimate current vaccines effectiveness on B.1.1.7 variant, we conducted the separate compartments for wildtype and B.1.1.7 to dynamically simulate total infections and deaths under the vaccine protection, which were calibrated by daily reported COVID-19 infection cases and death cases. With the known vaccine effectiveness on wildtype and its proportion of new infections, we calculated the infections and deaths caused by B.1.1.7 from total and further estimated the vaccine effectiveness on B.1.1.7.

132

The estimate is dependent on the model calibration and parameters optimization. To validate the reliability of estimated vaccine effectiveness, we conducted an extra comparison of the total variance (the sum of square errors of four types of data) in 0-100% vaccine effectiveness on B.1.1.7 variant (**Figure S2**). The minimum of total variance means the best match of simulations and actual epidemic data, at this point the estimated vaccine effectiveness was the best suit for available epidemic data.

139

140 **3. Model prediction**

141

142 **3.1 Construction of scenarios**

The emergence of E484K substitution in B.1.1.7 or other new variants may potentially reduce 143 the effectiveness of the existing vaccines. We evaluate its impact on the COVID-19 epidemic 144 when the vaccine effectiveness (1) adopts the model-estimated value for B.1.1.7 (baseline 145 scenario); reduces to (2) 75%; (3) 50% and (4) 25%. For each scenario, we calculated the 146 cumulative infections and deaths due to COVID-19 over the next 12 months (1st June 2021 to 147 31st May 2022). Since we did not know the viral properties of potential new variants, we also 148 simulated nine scenarios with varying viral transmissibility and mortality as a sensitivity 149 analysis (Figure 2). 150

151

152 **3.2 Impact of social restoration**

Social restoration means releasing restrictions of daily shopping, working, meeting or gathering, and traveling, which would significantly enlarge the force of infection for both wild type and B.1.1.7 variant. To assess the timing of social restoration and herd immunity, we conducted three situations of social restoration at 60%, 65%, and 70% vaccination coverage levels and calculated the cumulative infections and deaths of COVID-19 over the next 12 months to evaluate their impact on the COVID-19 epidemic trend (Figure 3).

159

160 **3.3 Uncertainty and sensitivity analyses**

Based on the selected 100 parameter sets in model calibration, we produced the sensitivity analysis to accommodate the uncertainty of model parameters and determine the 95% CI of the cumulative COVID-19 infections and deaths. In addition, we also explore the impact on the epidemic trends of COVID-19 in several scenarios (new variants emerge with higher transmissibility, mortality, and lower vaccine effectiveness; social restoration; Figures 2-3). All analyses and simulations were performed in MATLAB R 2019b.

Parameter	Description	Range or 95% CI from NLS	Source	
1/k ₁	The mean incubation time (days)	5.2 (4.1-7.0)	[13]	
$1/k_2$	The mean time from undiagnosed mild/moderate stage to undiagnosed severe/critical stage (days)	10	[14]	
k ₃	The progression rate from diagnosed mild/moderate stage to diagnosed severe/critical stage	$0.0287~(0.0284\text{-}0.0291) \times k_2$	NLS	
$1/\alpha_1(t)$	The average period from symptoms onset to diagnose for mild/moderate cases (days)	Decreased by logistic function: Mar 1, 2020-May 31, 2022: 7.74 (7.65-7.82)-3.29 (3.25-3.33)	NLS	
$1/\alpha_2$	The average diagnose period for severe/critical cases (days)	2.23 (2.20-2.25)	NLS	
$1/\gamma_0$	The mean time for natural recovery (days)	10.65 (10.53-10.78)	NLS	
$1/\gamma_1$	The average recovery period for diagnosed mild/moderate cases (days)	7	[15, 16]	
$1/\gamma_2$	The average recovery period for diagnosed severe/critical cases (days)	$21 - 1/\alpha_2$	[16]	
r	The mean number of members in a family	4	[2]	
$1/\xi$	The mean recovery period for infected family members (days)	28	[3]	
E(0)	The initial value of latent individuals infected by widetype	190 (188-192)	NLS	
E _m (0)	The initial value of latent individuals infected by B.1.1.7	62548 (61813-63282)	NLS	
A(0)	The initial value of asymptomatic individuals infected by widetype	190 (188-192)	NLS	
$I_1(0)$	The initial value of undiagnosed mild/moderate cases infected by widetype	190 (188-192)	NLS	
$I_2(0)$	The initial value of undiagnosed severe/critical cases infected by widetype	190 (188-192)	NLS	
β	The per-act transmission probability in contact with infected individuals with symptoms by widetype	0.0303 (0.0299-0.0306)	NLS	
β_m	The per-act transmission probability in contact with infected individuals with symptoms caused by B.1.1.7	59% (56-63%)× β + β	NLS and literatures [5]	
8	The reduction in per-act transmission probability if infection is in latent and asymptomatic stage	75%	[4]	

Table S1. The values of parameters based on references or estimation by nonlinear least-squares (NLS) method in the US.

Parameter	Description	Range or 95% CI from NLS	Source
ρ	The probability that an individual is asymptomatic	0.4964 (0.4904-0.5023)	NLS
ϵ_V	The weighted effectiveness of vaccines (Pfizer, Moderna and J&J Jensen)	91.4% (92.6%, 92.1%, 66.9%)	[17-19]
$\epsilon_{m,V}$	The effectiveness of vaccines for B.1.1.7	88.5% (87.4-89.5%)	NLS
$ heta_1$	The effectiveness of mask in preventing infection	0.85 (0.66-0.93)	[6]
θ_2	The effectiveness of handwashing in preventing infection	0.42 (0.1-0.95)	[7]
$\mu_1(t)$	Disease-induced death rate of undiagnosed severe/critical cases infected by widetype	Decreased by logistic function: Mar 1, 2020-May 31, 2022: 0.0527 (0.0521-0.0533)-0.0224 (0.0222- 0.0226)	NLS
$\mu_2(t)$	Disease-induced death rate of diagnosed severe/critical cases infected by widetype	$0.0358 (0.0354 - 0.0363) \times \mu_1(t)$	NLS
$\mu_{\mathrm{m,1}}\left(\mathrm{t}\right)$	Disease-induced death rate of undiagnosed severe/critical cases infected by B.1.1.7	45% (18-78%)× $\mu_1(t) + \mu_1(t)$	NLS and literatures [20]
$\mu_{\mathrm{m,2}}(t)$	Disease-induced death rate of diagnosed severe/critical cases infected by B.1.1.7	$0.0358 (0.0354 - 0.0363) \times \mu_{m,1}(t)$	NLS and literatures [20]
$m_{pub,ini}$	Base daily contact number in the public settings	34.81 (34.41-35.20)	NLS
$m_{pri,ini}$	Base daily contact number in the households	4	[21]
$m_{pub}(t)$	The percentage of base daily contact number in the public settings	Shown in the Table S2	NLS and literatures [8, 9]
$m_{pri}(t)$	The percentage of base daily contact number in the households	Shown in the Table S2	NLS and literatures [8, 9]
$p_1(t)$	The usage percentage of face mask in the public settings	Shown in the Table S2	NLS and literatures [8]
q(t)	The usage percentage of handwashing	Shown in the Table S2	NLS and literatures [22, 23]
w(t)	The vaccination rate for susceptible individuals (per day)	Shown in the Table S2	NLS

Table S2. The details of Logistic function based on trend of social interventions of public surveys or estimation by nonlinear least-squares (NLS)

172 method.

parameters		Mar 1 2020- Jun 4, 2020	Mar 1 2020- Sep 5, 2020	Mar 1, 2020- Mar 31, 2022	Jun 5 2020- Sep 5 2020	Sep 6 2020- Dec 17, 2020	Dec 18 2020- Mar 3, 2021	Mar 4, 2021- Apr 2, 2021	Apr 3, 2021- May31, 2022
	Initial	100.00%			16.8%	45.2%	66.8%	62.5%	83.5%
m (t)	end value	16.8%			45.2%	66.8%	62.5%	83.5%	67.3%
$m_{pub}(t)$	rate	0.2159			0.2159	0.1699	0.1699	0.2159	0.2159
	mid-point	Api 2, 2020			Jun 4, 2020	Sep 5, 2020	Dec 17, 2020	Mar 3, 2021	Apr 2, 2021
	Initial	100.00%	_	_	200.00%	165.9%	139.9%	145.1%	119.9%
m (t)	end value	200.00%			165.9%	139.9%	145.1%	119.9%	139.3%
$m_{pri}(t)$	rate	0.2159	_	_	0.2159	0.1699	0.1699	0.2159	0.2159
	mid-point	Api 2, 2020	_	_	Jun 4, 2020	Sep 5, 2020	Dec 17, 2020	Mar 3, 2021	Apr 2, 2021
	Initial		0.00%			51.4%	45.9%	64.3%	46.9%
m (t)	end value		51.4%		_	45.9%	64.3%	46.9%	62.4%
$p_{pub}(t)$	rate		0.2159			0.1699	0.1699	0.2159	0.2159
	mid-point		Jul 12, 2020			Sep 5, 2020	Dec 17, 2020	Mar 3, 2021	Apr 2, 2021
	Initial			77%	_				
$\alpha(t)$	end value			95%					
q(t)	rate			0.2159					
	mid-point	_	_	Api 2, 2020					
	Initial			0	_				
(+)	end value		_	0.0188	_		—		—
w(t)	rate		_	0.0215	_		—		—
	mid-point	_	_	Apr 10, 2021	_		_		_




Figure S1. A schematic flow diagram of the transmission of COVID-19 and its mutants.






Figure S2. The validation for estimated vaccine effectiveness on B.1.1.7 variant. The four colored line denote the average standardized variance between four types of simulated and reported data in 0-100% vaccine effectiveness on B.1.1.7 variant. The arrows point to the lowest point of the simulated curve.

Supplement Reference

- Shen M, Zu J, Fairley CK, Pagán JA, An L, Du Z, Guo Y, Rong L, Xiao Y, Zhuang G *et al*: Projected
 COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine
 and implications for social distancing and face mask use. *Vaccine* 2021, 39(16):2295-2302.
- 1862.AveragesizeofhouseholdsintheU.S.2019.Statista.187[https://www.statista.com/statistics/183648/average-size-of-households-in-the-us/]Statista
- 3. Shen M, Peng Z, Guo Y, Rong L, Li Y, Xiao Y, Zhuang G, Zhang L: Assessing the effects of metropolitan-wide quarantine on the spread of COVID-19 in public space and households. Int J Infect Dis 2020, 96:503-505.
- Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, Jit M, Klepac P: The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Health 2020, 5(5):e261-e270.
- Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW,
 Tully DC, Washburne AD *et al*: Estimated transmissibility and impact of SARS-CoV-2 lineage
 B.1.1.7 in England. *Science* 2021.
- 6. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ: Physical distancing, face masks, and
 eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a
 systematic review and meta-analysis. *Lancet* 2020, 395(10242):1973-1987.
- Fung IC, Cairneross S: Effectiveness of handwashing in preventing SARS: a review. Trop Med Int Health 2006, 11(11):1749-1758.
- 8. Delphi survey results about the spread and impact of the COVID-19 pandemic in the United States
 [https://delphi.cmu.edu/covidcast/survey-results/?region=9&date=20210511]
- 9. Understand the impact of COVID-19 using real data [<u>https://www.unacast.com/covid19/social-distancing-scoreboard</u>]
- 206 10. Coronavirus Resource Center: COVID-19 Tracking [https://coronavirus.jhu.edu]
- 207 11. COVID-19 Vaccinations in the United States [https://covid.cdc.gov/covid-data-tracker/#vaccinations]
- 208 12. Variant Proportions in the US [https://covid.cdc.gov/covid-data-tracker/#variant-proportions]
- 13. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY *et al*: Early
 Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J
 Med 2020, 382(13):1199-1207.
- 14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y *et al*: Clinical
 Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
 Wuhan, China. Jama 2020, 323(11):1061-1069.
- 15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X *et al*: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020, 395(10223):497-506.
- 217 16. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)
 218 [https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus 219 disease-2019-(covid-19)]
- 17. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N,
 Creech CB *et al*: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021,
 384(5):403-416.
- 18. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira
 ED, Zerbini C *et al*: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med
 2020, 383(27):2603-2615.
- 19. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C,
 Fennema H, Spiessens B *et al*: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against
 Covid-19. N Engl J Med 2021.
- 20. Kow CS, Merchant HA, Hasan SS: Mortality risk in patients infected with SARS-CoV-2 of the
 lineage B.1.1.7 in the UK. J Infect 2021.
- 231 21. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS: Strategies for mitigating an
 232 influenza pandemic. *Nature* 2006, 442(7101):448-452.
- 233 22. Park CL, Russell BS, Fendrich M, Finkelstein-Fox L, Hutchison M, Becker J: Americans' COVID-19
 234 Stress, Coping, and Adherence to CDC Guidelines. J Gen Intern Med 2020, 35(8):2296-2303.
- 235 23. Pogrebna G, Kharlamov A: The Impact of Cross-Cultural Differences in Handwashing Patterns on
 236 the COVID-19 Outbreak Magnitude; 2020.
- 237